Management
Michael Stocum
Chief Executive Officer
Read more

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Michael Stocum
Chief Executive Officer

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Nitzan Rosenfeld
Chief Scientific Officer

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

Philip Perez
Chief Commercial Officer

Philip brings to Inivata more than 20 years of industry-related experience in molecular diagnostics, clinical oncology, and precision medicine.  He has worked with companies including Becton Dickinson, Johnson & Johnson, Agendia, and Caris Life Sciences at various commercial stages including the development of a BD joint venture with QIAGEN to create PAXgene products, the commercial launch of the Veridex Circulating Tumor Cell (CTC) technology, the launch and positive coverage determination for the MammaPrint assay in the US, and the launch of the Caris Centers of Excellence for Precision Medicine network.  Throughout his career, Philip has garnered respect and increasing leadership roles to drive sales, improve client services, develop marketing, and expand managed care organizations.

Philip holds a BA in English from the University of Michigan at Ann Arbor and an MBA from the University of North Carolina at Chapel Hill.

Clive Morris
Chief Medical Officer

Clive joins Inivata from Health Innovation Manchester, an initiative to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services.  Previous to this, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ.  Clive is a proven leader in the biopharmaceutical industry and has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products.  He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester.  Clive is also a non-executive director of Wheatsheaf investments and the recently launched InnovateUK Medicines Discovery Catapult.

John Beeler
VP, Corporate and Business Development

John focuses on overseeing our business development related activities including partnerships with diagnostic and biopharmaceutical companies and academic institutions internationally. John has over 20 years of product and business development experience spanning the pharmaceutical and diagnostic industry including a history of having established and managed partnerships with leading pharmaceutical companies. Most recently he served as Director, Theranostics and Business Development at bioMerieux where he was responsible for executing companion diagnostic development and commercialization agreements with GlaxoSmithKline, Novartis and Gilead. John has published and presented at several scientific meetings and symposia on the topic of developing companion diagnostics and implementing personalized medicine initiatives. Dr. Beeler holds a Masters degree in biology from Villanova University and a Ph.D in pharmacology from the University of South Carolina School of Medicine.

James Clark
VP, Clinical Laboratory Operations

Dr Clark is responsible for set up and management of Inivata’s clinical testing laboratories in the US and Europe. He will also be closely involved with product development and commercialisation.

Dr Clark brings executive management level experience at the nexus of the therapeutic and diagnostic industries, specialising in Companion Diagnostics (CDx) and Next Generation Sequencing (NGS). During his career he has worked extensively in therapeutics and molecular oncology, developing and commercialising over 10 diagnostic products. James brings US-based CLIA lab experience having held executive roles in a number of oncology companies including VP Research and Development at MDx Health and COO at Response Genetics.

Dr Clark has a BSc in Microbiology and obtained his PhD from the Biochemistry Department of Glasgow University.

Tim Shannon
Chief Financial Officer

Tim joins Inivata from Baxano Surgical and Talecris Biotherapeutics, where he formulated and implemented financial controls and process improvements that supported business growth and expansion. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards long-term business planning and commercialization of its InVision® product line. While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management.

Vincent Plagnol
VP, Computational Biology

Vincent was educated in Paris, France, where he obtained his bachelor of mathematics at the Ecole Normale Supérieure and an MSc in Theoretical Probability. After his PhD in Applied Mathematics and Computational Biology at the University of Southern California, he moved to the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory at the University of Cambridge in 2006 to study the genetics of autoimmune disorders, in particular type 1 diabetes. Following this postdoc in Cambridge, he became a Lecturer (2009), and then a Reader (2013), in Statistical Genetics at the University College London (UCL) Genetics Institute (UGI). At the UGI he leads a computational research group working at the intersection between statistics, computer science and genetics, with a focus on translational research, in particular rare disease genetics and non-invasive prenatal diagnostics based on cell-free fetal DNA.

He joined Inivata as the first employee and has been a driving force in developing the analytical process that optimizes the precision of the eTAm-Seq™ assay.

Jamie Platt
Head of US Commerical Laboratory Operations

Dr. Platt received her Ph.D. in Molecular & Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley. She has extensive expertise in sequencing and molecular systematics, including population genetics. During her 15 years in clinical diagnostics, Dr. Platt has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays. Dr. Platt has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare.

Founders
Nitzan Rosenfeld
Chief Scientific Officer

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

James Brenton
Clinical Advisor

James is a co-founder of Inivata, and a senior group leader at the Cancer Research UK Cambridge Institute, leading the Functional Genomics of Ovarian Cancer laboratory. His research focuses on using clinical studies to test and identify predictive markers for therapy in ovarian cancer and to identify mechanisms of drug resistance. His group was the first to show that mutations in the TP53 gene are ubiquitous in the commonest form of ovarian cancer (high-grade serous ovarian carcinoma) and he has used this discovery to develop personalized circulating tumour DNA assays to measure treatment response in ovarian cancer.

He is the chair of the Informatics Advisory Group for the national CR-UK Stratified Medicine Programme and was previously Vice-Chair of the CR UK Biomarkers and Imaging Discovery and Development Committee. He is a member of the international Ovarian Tumor Tissue Analysis (OTTA) Consortium steering committee, the SGCTG Protocol Review Committee and the NCRI ovarian cancer subgroup.

James qualified in medicine from University College London and trained in medical oncology at the Royal Marsden Hospital, Princess Margaret Hospital, Toronto and the Department of Oncology, University of Cambridge. His PhD work was carried out at the Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental Biology.

Davina Gale
Business Development Manager

Davina is a co-founder of Inivata, and brings 20 years’ experience in the pharmaceutical industry working for GSK and SmithKline Beecham, primarily in the identification and validation of novel genomic biomarkers for neurological and respiratory disease, including transitioning their use into Phase I/IIa clinical trials.

In 2009 Davina joined as Lab Manager of the Molecular and Computational Diagnostics group at the Cancer Research UK Cambridge Institute, University of Cambridge, where she established protocols and lab infrastructure for the identification of rare mutations in patient plasma to demonstrate the potential of ctDNA as a non-invasive ‘liquid’ biopsy for personalised cancer therapy.

Tim Forshew
Head of Technology Development

Tim is a co-founder of Inivata and an honorary lecturer at UCL. His team focuses on the development of cutting-edge technologies for the analysis of cancer mutations. His academic research is based on detecting cancer DNA released by solid tumours into bodily fluids such as blood and urine. Major clinical areas of focus within his UCL research are sarcoma, liver cancer and childhood brain tumours.
During his time at Cambridge University Tim was part of the team that first demonstrated detecting solid tumour mutations through next generation sequencing of blood plasma. As a postdoctoral Researcher at QMUL he won the 2009 Jeremy Jass Prize for his role in identifying fusion genes in Pilocytic Astrocytoma.

Board Members
Michael Stocum
Chief Executive Officer
Read more

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Jeff Buchalter
Non-executive Chairman

Jeff joins Inivata after a long and successful career in the bio/pharmaceutical industry most recently as Chief Executive Officer of Archimedes Pharma Ltd.  His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organisations.  He brings extensive commercial and drug development experience in oncology and other therapeutic areas.

Jeff has been recognised for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field.  He has also been a Collaborating Partner in the President’s National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States.

Jeff received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.

Patrick Terry
Non-executive Director

In 2000, Patrick and a group of prominent leaders in the fields of genomics, bioinformatics and biotechnology founded Genomic Health, Inc. (NASDAQ: GHDX), a pioneering personalized medicine company based in California. He has more recently acted as an advisor to multiple life sciences ventures and founded two other applied genetics companies. Patrick has served on the boards of companies inNorth America and Europe and is currently Chief Commercial Officer at Claritas Genomics.

Patrick has created numerous foundations and philanthropic organisations including the Personalized Medicine Coalition (PMC) and the European Personalized Medicine Association (EPEMED). These organizations were established to advance the understanding of personalised medicine.

He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the field of genetics, personalized medicine, and biomedical research and acts as an editor and advisor to numerous organisations.

Rob Woodman
Non-executive Director

Rob Woodman is Director of Healthcare Investments at Imperial Innovations, and currently serves on the boards of Mission Therapeutics, Stanmore Implants, and Nascient Therapeutics. Rob joined Innovations in 2012 and was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. Rob’s experience ranges from technology transfer with Cancer Research Technology (CRUK) through to pharmaceutical consultancy with IMS Health.

Rob holds an MSc in Biochemistry from the University of Oxford and a PhD in Oncology from the University of Cambridge.

Robert Tansley
Non-executive Director

Robert joined Cambridge Innovation Capital as Investment Director in January 2014. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte®. Ten years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.

Robert qualified in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.

Michael Stocum
Chief Executive Officer

In his 25-year industry career, Michael has impacted products across several therapeutic areas. He has held corporate roles in pharmaceuticals with GlaxoWellcome/GSK, biologics at Organon (now Merck) and molecular diagnostics at Organon Teknika (now bioMerieux) plus two biotech start-ups. His roles have spanned bench research to product, business and commercial development, delivering or enhancing multiple innovative molecular diagnostics such as HIV-1 RNA and HBV DNA viral load tests along with numerous medicines in several disease areas including cancer (Onco-TICE BCG, Tykerb/Tyverb and Votrient), infectious diseases (abacavir) and cardiometabolic diseases (Avandia).

In 2004 Michael founded Personalized Medicine Partners to provide global strategic business and operational capabilities for biopharmaceutical, diagnostic and research/clinical services companies, specialising in product development and commercialisation of integrated therapeutic and biomarker/companion diagnostic programmes. Michael is the founding and past chair of the Personalized Medicine Division of the American Association for Clinical Chemistry and is active in the Personalized Medicine Coalition, a non-profit dedicated to advancing the field of Personalized Medicine. He also serves on the Industry Advisory Board for the Professional Science Masters program at NC State University (NCSU).

Michael earned dual B.S. degrees in Biochemistry and Microbiology from North Carolina State University, with a minor in Genetics and an M.S. in Biotechnology Management, while conducting two years of academic research assistantships at NCSU and the National Institutes of Health.

Nitzan Rosenfeld
Chief Scientific Officer

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. In 2009 Nitzan joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge. His research group combines molecular technologies with genomic approaches to develop new diagnostic strategies. The focus of current research, the application of circulating tumour DNA for personalised cancer diagnostics, formed the basis of Inivata. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  At the end of 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD.

Keith Blundy
Non-executive Director

Keith joined Cancer Research Technology in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc. in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia.

After completing a PhD at the John Innes Institute and a post-doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development.
Keith has a BSc and PhD in genetics and an MBA from the London Business School.

Jeanne Bolger
Non-executive Director

Jeanne joined Johnson & Johnson Innovation – JJDC, Inc as Vice President, Venture Investments, in February 2013. She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Jeanne has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK. In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

Peter Wrighton-Smith
Non-executive Director

Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Glob al PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions. Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model. Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013. Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.